Weiping Zou

List of Publications by Year in Descending Order

154 papers	31,421 citations	74 h-index	163 g-index
163 ext. papers	38,185 ext. citations	14.8 avg, IF	7.48 L-index

#	Paper	IF	Citations
154	CD8 T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4.. *Cancer Cell*, **2022**,	24.3	12
153	DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway.. *OncoImmunology*, **2022**, 11, 2052640	7.2	0
152	Metabolism drives macrophage heterogeneity in the tumor microenvironment.. *Cell Reports*, **2022**, 39, 110609	10.6	2
151	Uncovering the Immunoregulatory Function and Therapeutic Potential of the PD-1/PD-L1 Axis in Cancer. *Cancer Research*, **2021**, 81, 5141-5143	10.1	1
150	IFN Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer. *Clinical Cancer Research*, **2021**, 27, 3661-3673	12.9	2
149	Autophagy in tumour immunity and therapy. *Nature Reviews Cancer*, **2021**, 21, 281-297	31.3	50
148	Tissue-resident memory T cells in tumor immunity and immunotherapy. *Journal of Experimental Medicine*, **2021**, 218,	16.6	15
147	Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. *Cancer Cell*, **2021**, 39, 480-493.e6	24.3	20
146	Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner. *Molecular Cancer Research*, **2021**, 19, 1571-1582	6.6	0
145	LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. *Nature Cell Biology*, **2021**, 23, 526-537	23.4	22
144	Tim-4 cavity-resident macrophages impair anti-tumor CD8 T cell immunity. *Cancer Cell*, **2021**, 39, 973-988.e9	24.3	13
143	Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation. *Cancer Discovery*, **2021**, 11, 1826-1843	24.4	9
142	The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. *Nature Immunology*, **2021**, 22, 460-470	19.1	11
141	Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer. *Nature Cancer*, **2021**, 2, 978-993	15.4	4
140	Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-[(ROR) Agonist for Use in Treating Cancer. *Journal of Medicinal Chemistry*, **2021**, 64, 13410-13428	8.3	2
139	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. *Nature Medicine*, **2021**, 27, 152-164	50.5	117
138	Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis. *JCI Insight*, **2020**, 5,	9.9	21

137	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. *Journal of Clinical Investigation*, **2020**, 130, 2712-2726	15.9	45
136	Amino Acids and Their Transporters in T Cell Immunity and Cancer Therapy. *Molecular Cell*, **2020**, 80, 384-395	17.6	30
135	Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice. *Gastroenterology*, **2020**, 158, 1417-1432.e11	13.3	22
134	Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. *Nature Cancer*, **2020**, 1, 1097-1112	15.4	52
133	Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. *Nature*, **2020**, 585, 277-282	50.4	98
132	A 16q22.1 variant confers susceptibility to colorectal cancer as a distal regulator of ZFP90. *Oncogene*, **2020**, 39, 1347-1360	9.2	11
131	Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. *Cancer Discovery*, **2019**, 9, 1673-1685	24.4	252
130	CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor In Active Crohn's Disease. *Journal of Crohn's and Colitis*, **2019**, 13, 905-915	1.5	19
129	ROR Agonists Enhance the Sustained Antitumor Activity through Intrinsic Tc17 Cytotoxicity and Tc1 Recruitment. *Cancer Immunology Research*, **2019**, 7, 1054-1063	12.5	4
128	Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. *Cancer Research*, **2019**, 79, 3940-3951	10.1	89
127	CD8 T cells regulate tumour ferroptosis during cancer immunotherapy. *Nature*, **2019**, 569, 270-274	50.4	632
126	Cancer nanomedicine for combination cancer immunotherapy. *Nature Reviews Materials*, **2019**, 4, 398-414	73.3	372
125	Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry. *Journal of Visualized Experiments*, **2019**,	1.6	3
124	LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc. *Nature Communications*, **2019**, 10, 3499	17.4	126
123	Rewiring regulatory T cells for tumour killing. *Nature Biomedical Engineering*, **2019**, 3, 766-767	19	1
122	Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells. *Annals of Surgical Oncology*, **2019**, 26, 2821-2830	3.1	8
121	Immunotherapy in Ovarian Cancer. *Surgical Oncology Clinics of North America*, **2019**, 28, 447-464	2.7	17
120	A PHD in immunosuppression: oxygen-sensing pathways regulate immunosuppressive Tregs. *Journal of Clinical Investigation*, **2019**, 129, 3524-3526	15.9	4

119	Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nature Medicine*, **2018**, 24, 541-550	50.5	1772
118	miR-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer. *Cancer Research*, **2018**, 78, 1751-1765	10.1	21
117	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. *Cell*, **2018**, 173, 1770-1782.e14	56.2	256
116	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. *Journal of Clinical Investigation*, **2018**, 128, 805-815	15.9	252
115	CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy **2018**, 23-39		5
114	Spatial and phenotypic immune profiling of metastatic colon cancer. *JCI Insight*, **2018**, 3,	9.9	40
113	Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28. *Journal of Surgical Research*, **2018**, 232, 570-577	2.5	10
112	Priming of Adoptively Transferred T Cells with a ROR□Agonist Confers Durable Memory and Stemness. *Cancer Research*, **2018**, 78, 3888-3898	10.1	21
111	Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. *Cell Metabolism*, **2018**, 28, 87-103.e6	24.6	140
110	Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. *Journal of Immunology* , **2018**, 201, 814-820	5.3	10
109	IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. *Cancer Research*, **2017**, 77, 2735-2745	10.1	93
108	Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. *Nature Reviews Immunology*, **2017**, 17, 559-572	36.5	865
107	Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. *Nature Immunology*, **2017**, 18, 1332-1341	19.1	337
106	Phenotype and tissue distribution of CD28H immune cell subsets. *OncoImmunology*, **2017**, 6, e1362529	7.2	8
105	ARID1A-mutated ovarian cancers depend on HDAC6□activity. *Nature Cell Biology*, **2017**, 19, 962-973	23.4	124
104	Regulation of immune-related diseases by multiple factors of chromatin, exosomes, microparticles, vaccines, oxidative stress, dormancy, protein quality control, inflammation and microenvironment: a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine on Tumor Immunology. *Acta Pharmaceutica Sinica B*, **2017**,	15.5	3
103	Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. *Cell*, **2017**, 170, 548-563.e16	56.2	765
102	Suppression of FIP200 and autophagy by tumor-derived lactate promotes na□e T cell apoptosis and affects tumor immunity. *Science Immunology*, **2017**, 2,	28	44

101	The Role of Tumor Microenvironment in Cancer Immunotherapy. *Advances in Experimental Medicine and Biology*, **2017**, 1036, 51-64	3.6	64
100	Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. *Journal of Clinical Investigation*, **2017**, 127, 4449-4461	15.9	79
99	Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling. *OncoImmunology*, **2016**, 5, e1082704	7.2	24
98	Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma. *OncoImmunology*, **2016**, 5, e1105430	7.2	21
97	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. *Science Translational Medicine*, **2016**, 8, 328rv4	17.5	1281
96	Synthetic ROR agonists regulate multiple pathways to enhance antitumor immunity. *OncoImmunology*, **2016**, 5, e1254854	7.2	47
95	Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. *OncoImmunology*, **2016**, 5, e1074374	7.2	112
94	Biological and pathological activities of interleukin-22. *Journal of Molecular Medicine*, **2016**, 94, 523-34	5.5	73
93	PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. *Cancer Research*, **2016**, 76, 275-82	10.1	148
92	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. *Nature Immunology*, **2016**, 17, 95-103	19.1	234
91	Regulatory T Cells in Tumor Immunity **2016**, 451-459		2
90	Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. *Cancer Research*, **2016**, 76, 3156-65	10.1	155
89	Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. *Cell*, **2016**, 165, 1092-1105	36.2	222
88	LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern. *Cancer Discovery*, **2016**, 6, 784-801	24.4	245
87	OCT1 is a determinant of synbindin-related ERK signalling with independent prognostic significance in gastric cancer. *Gut*, **2015**, 64, 37-48	19.2	48
86	Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. *Nature*, **2015**, 527, 249-53	50.4	629
85	Dendritic cells are stressed out in tumor. *Cell Research*, **2015**, 25, 989-90	24.7	3
84	Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. *Cancer Immunology Research*, **2015**, 3, 1236-47	12.5	260

83	Depletion of androgen receptor (AR) in mesenchymal stem cells (MSCs) inhibits induction of CD4+CD25+FOX3+ regulatory T (Treg) cells via androgen TGF- interaction. *Journal of Applied Biomedicine*, **2015**, 13, 263-271	0.6	1
82	Myeloid cells in hepatocellular carcinoma. *Hepatology*, **2015**, 62, 1304-12	11.2	83
81	Consensus nomenclature for CD8 T cell phenotypes in cancer. *OncoImmunology*, **2015**, 4, e998538	7.2	101
80	T Cell Fate in the Tumor Microenvironment. *Cancer Drug Discovery and Development*, **2015**, 53-74	0.3	
79	Chemokines and cellular plasticity of ovarian cancer stem cells. *Oncoscience*, **2015**, 2, 615-6	0.8	8
78	MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. *Scientific Reports*, **2014**, 4, 6145	4.9	47
77	IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. *Immunity*, **2014**, 40, 772-784	32.3	238
76	Long noncoding RNA GAPLINC regulates CD44-dependent cell invasiveness and associates with poor prognosis of gastric cancer. *Cancer Research*, **2014**, 74, 6890-902	10.1	219
75	Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. *Gastroenterology*, **2014**, 147, 1393-404	13.3	380
74	ArhGAP30 promotes p53 acetylation and function in colorectal cancer. *Nature Communications*, **2014**, 5, 4735	17.4	44
73	MiR-194 deregulation contributes to colorectal carcinogenesis via targeting AKT2 pathway. *Theranostics*, **2014**, 4, 1193-208	12.1	49
72	Classification of current anticancer immunotherapies. *Oncotarget*, **2014**, 5, 12472-508	3.3	301
71	TMEFF2 deregulation contributes to gastric carcinogenesis and indicates poor survival outcome. *Clinical Cancer Research*, **2014**, 20, 4689-704	12.9	30
70	Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. *Immunity*, **2013**, 39, 611-21	32.3	294
69	NF-B inhibits osteogenic differentiation of mesenchymal stem cells by promoting catenin degradation. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 9469-74	11.5	215
68	Th17 Cells in Cancer **2013**, 129-147		
67	T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. *Current Opinion in Immunology*, **2013**, 25, 214-21	7.8	413
66	T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment **2013**, 17-44		

65	T cells and costimulation in cancer. *Cancer Journal (Sudbury, Mass)*, **2013**, 19, 473-82	2.2	17
64	Synbindin in extracellular signal-regulated protein kinase spatial regulation and gastric cancer aggressiveness. *Journal of the National Cancer Institute*, **2013**, 105, 1738-49	9.7	29
63	Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. *American Journal of Clinical Nutrition*, **2013**, 97, 1044-52	7	183
62	TLR2 mediates Helicobacter pylori-induced tolerogenic immune response in mice. *PLoS ONE*, **2013**, 8, e74595	3.7	37
61	Therapeutic Targeting Regulatory T Cells in Tumor **2013**, 585-602		
60	The B7 homologues and their receptors in hematologic malignancies. *European Journal of Haematology*, **2012**, 88, 465-75	3.8	13
59	Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. *International Journal of Cancer*, **2012**, 130, 29-39	7.5	198
58	Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival. *Cancer Investigation*, **2012**, 30, 689-97	2.1	23
57	Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. *Hepatology*, **2012**, 56, 1342-51	11.2	305
56	Regulatory T cells in human ovarian cancer. *Journal of Oncology*, **2012**, 2012, 345164	4.5	16
55	Targeting regulatory T cells. *Targeted Oncology*, **2012**, 7, 15-28	5	57
54	Bone marrow and the control of immunity. *Cellular and Molecular Immunology*, **2012**, 9, 11-9	15.4	168
53	Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. *OncoImmunology*, **2012**, 1, 152-161	7.2	97
52	Interleukin-10 ablation promotes tumor development, growth, and metastasis. *Cancer Research*, **2012**, 72, 420-9	10.1	108
51	Th17 cells have stem cell-like features and promote long-term immunity. *OncoImmunology*, **2012**, 1, 516-519	7.2	39
50	Relationship Between Th17 and Regulatory T Cells in the Tumor Environment **2012**, 175-193		
49	Deciphering the role of Th17 cells in human disease. *Trends in Immunology*, **2011**, 32, 603-11	14.4	173
48	T lymphocytes to IDO+ cells: check. *Blood*, **2011**, 117, 2082-3	2.2	4

47	Dual biological effects of the cytokines interleukin-10 and interferon-□*Cancer Immunology, Immunotherapy*, **2011**, 60, 1529-41	7.4	101
46	Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. *Journal of Translational Medicine*, **2011**, 9, 217	8.5	23
45	Th17 cells in cancer: help or hindrance?. *Carcinogenesis*, **2011**, 32, 643-9	4.6	141
44	Human TH17 cells are long-lived effector memory cells. *Science Translational Medicine*, **2011**, 3, 104ra100	17.5	195
43	IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. *Journal of Immunology*, **2011**, 186, 4388-95	5.3	198
42	Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. *Genes and Development*, **2011**, 25, 1510-27	12.6	276
41	Antigen-presenting cell (APC) subsets in ovarian cancer. *International Reviews of Immunology*, **2011**, 30, 120-6	4.6	27
40	T(H)17 cells in tumour immunity and immunotherapy. *Nature Reviews Immunology*, **2010**, 10, 248-56	36.5	460
39	A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease. *Journal of Immunology*, **2010**, 185, 3866-72	5.3	47
38	Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. *Gastroenterology*, **2010**, 138, 1046-54	13.3	235
37	Response: Endogenous IL-17, tumor growth, and metastasis. *Blood*, **2010**, 115, 2556-2557	2.2	14
36	Prognostic significance of regulatory T cells in tumor. *International Journal of Cancer*, **2010**, 127, 748-58	7.5	83
35	Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. *Journal of Immunology*, **2009**, 183, 7297-306	5.3	49
34	FOXP3 defines regulatory T cells in human tumor and autoimmune disease. *Cancer Research*, **2009**, 69, 3995-4000	10.1	163
33	Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. *Cancer Research*, **2009**, 69, 8067-75	10.1	258
32	Endogenous IL-17 contributes to reduced tumor growth and metastasis. *Blood*, **2009**, 114, 357-9	2.2	307
31	Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. *Blood*, **2009**, 114, 1141-9	2.2	579
30	Modeling dynamic changes in type 1 diabetes progression: quantifying beta-cell variation after the appearance of islet-specific autoimmune responses. *Mathematical Biosciences and Engineering*, **2009**, 6, 753-78	2.1	13

29	Inhibitory B7-family molecules in the tumour microenvironment. *Nature Reviews Immunology*, **2008**, 8, 467-77	36.5	1165
28	Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. *Cancer Research*, **2008**, 68, 5432-8	10.1	55
27	Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. *Journal of Immunology*, **2008**, 181, 4733-41	5.3	367
26	Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. *Journal of Immunology*, **2008**, 181, 5842-6	5.3	64
25	Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. *Journal of Immunology*, **2007**, 179, 1423-6	5.3	143
24	Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. *Journal of Immunology*, **2007**, 178, 6730-3	5.3	340
23	Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. *Cancer Research*, **2007**, 67, 7487-94	10.1	129
22	Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 4324-8	5.9	22
21	Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. *Cancer Research*, **2007**, 67, 8900-5	10.1	254
20	Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. *Journal of Immunology*, **2006**, 177, 40-4	5.3	221
19	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. *Journal of Experimental Medicine*, **2006**, 203, 871-81	16.6	548
18	Regulatory T-cell compartmentalization and trafficking. *Blood*, **2006**, 108, 426-31	2.2	255
17	Manipulating T regulatory cells in cancer immunotherapy. *Expert Review of Dermatology*, **2006**, 1, 589-597		3
16	Regulatory T cells, tumour immunity and immunotherapy. *Nature Reviews Immunology*, **2006**, 6, 295-307	36.5	1581
15	Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. *Liver International*, **2005**, 25, 580-94	7.9	30
14	Immunosuppressive networks in the tumour environment and their therapeutic relevance. *Nature Reviews Cancer*, **2005**, 5, 263-74	31.3	1627
13	Regulatory T cells in ovarian cancer: biology and therapeutic potential. *American Journal of Reproductive Immunology*, **2005**, 54, 369-77	3.8	180
12	Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. *Cancer Research*, **2005**, 65, 5020-6	10.1	312

11	CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. *Cancer Research*, **2005**, 65, 465-72	10.1	285
10	Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. *Cancer Research*, **2004**, 64, 8451-5	10.1	343
9	Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. *Cancer Research* , **2004**, 64, 5535-8	10.1	230
8	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nature Medicine*, **2004**, 10, 942-9	50.5	3866
7	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. *Nature Medicine*, **2003**, 9, 562-7	50.5	980
6	Toxoplasma gondii-infected human myeloid dendritic cells induce T-lymphocyte dysfunction and contact-dependent apoptosis. *Infection and Immunity*, **2002**, 70, 1750-60	3.7	56
5	Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection. *European Journal of Immunology*, **2001**, 31, 3833-9	6.1	37
4	Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. *Nature Medicine*, **2001**, 7, 1339-46	50.5	547
3	Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. *Journal of Immunology*, **2000**, 165, 4388-96	5.3	116
2	Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. *Aids*, **1999**, 13, 455-63	3.5	37
1	Administration of interleukin 13 to simian immunodeficiency virus-infected macaques: induction of intestinal epithelial atrophy. *AIDS Research and Human Retroviruses*, **1998**, 14, 775-83	1.6	5